The global market for anti-VEGF (vascular endothelial growth factor) therapies targeting Age-Related Macular Degeneration (AMD) is experiencing significant growth, propelled by the increasing prevalence of AMD due to aging populations and lifestyle factors such as smoking and poor diet. Innovations in treatment, particularly the development of longer-acting anti-VEGF therapies like Roche's Vabysmo (faricimab), aim to reduce the treatment burden associated with frequent intravitreal injections. Furthermore, the anticipated approval of novel therapies for geographic atrophy (GA), a late-stage form of AMD, is expected to expand the treatable patient population. However, challenges such as high treatment costs and the off-label use of more affordable alternatives like Avastin may impact market dynamics. Key players in this market, including Regeneron Pharmaceuticals, Bayer AG, F. Hoffmann-La Roche Ltd, and Novartis AG, are focusing on strategic collaborations, product innovations, and geographic expansion to strengthen their market presence and address the evolving needs of patients and healthcare providers.
Global Age-Related Macular Degeneration (AMD) Disease - Anti VEGF Market is valued at USD 13.67 billion in 2023 and is expected to reach USD 22.95 billion by 2031, with a growing CAGR of 6.8% during the forecast period 2024 to 2031.
To know more, visit https://www.databridgemarketresearch.com/jp/reports/global-age-related-macular-degeneration-amd-disease-anti-vegf-market
Below are the Top Age-Related Macular Degeneration (AMD) Disease - Anti VEGF Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Regeneron Pharmaceuticals Inc.
|
Regeneron Pharmaceuticals is a biotechnology company that is a leading player in the anti-VEGF (vascular endothelial growth factor) market for treating age-related macular degeneration (AMD). Regeneron is well-known for its EYLEA (aflibercept), a drug used to treat both wet AMD and other retinal conditions. EYLEA is considered one of the most widely used treatments in the AMD space due to its effectiveness in slowing disease progression and improving vision.
|
|
North America, Asia-Pacific, and Europe
|
In November 2023, Regeneron Pharmaceuticals, Inc. announced long-term outcomes and new analyses of pivotal clinical data for EYLEA HD (aflibercept) Injection 8 mg at the American Academy of Ophthalmology (AAO) annual meeting in San Francisco. This is an investor event where the companies try to attract the investors, which helps the company increase the R&D.
|
|
2.
|
Novartis AG
|
Novartis is a global healthcare company and a prominent player in the ophthalmic treatment market, particularly for AMD. The company markets Lucentis (ranibizumab), an anti-VEGF therapy for wet AMD and other retinal conditions. Lucentis was one of the first FDA-approved treatments for wet AMD and continues to be a key product in Novartis’ ophthalmology portfolio, alongside its ongoing research into next-generation treatments for retinal diseases.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In March 2022, Novartis AG announced that Beovu (brolucizumab) 6 mg had been authorized by the European Commission (EC) to treat visual impairment caused by Diabetic Macular Edoema (DME). Beovu was initially approved by the EC in 20203 to treat wet age-related macular degeneration; the DME indication marks the medication's second approval. The ruling of the European Community (EC) applies to all 27 EU members and Liechtenstein, Iceland, and Norway.
|
|
3.
|
Bayer AG
|
Bayer is a global pharmaceutical and life sciences company, with a strong presence in ophthalmology. Bayer markets Eylea (aflibercept) outside the U.S., which competes directly with Regeneron’s Eylea. Bayer also offers Vitrakvi (larotrectinib) and Xarelto, but their ophthalmic division focuses heavily on retinal diseases, including AMD. Bayer continues to research and develop new anti-VEGF therapies to improve treatment options for patients with wet AMD.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In February 2023, Bayer AG submitted an application to the European Medicines Agency (EMA) for market authorization of aflibercept 8 mg about two main retinal eye diseases: Diabetic Macular Edoema (DME) and Neovascular (wet) Age-Related Macular Degeneration (nAMD). Bayer and Regeneron are developing aflibercept 8 mg together. In the US, Regeneron is the only owner of the rights to Eylea and aflibercept 8 mg. Outside of the US, Bayer has granted licenses for exclusive marketing rights, and the businesses split the earnings from Eylea sales evenly.
|
|
4.
|
IVERIC bio, Inc., An Astellas Company
|
IVERIC bio is a biotechnology company focused on developing therapies for retinal diseases, including age-related macular degeneration (AMD). It is the developer of Zimura (avacincaptad pegol), an investigational anti-VEGF treatment that targets complement factor C5, an immune system protein involved in retinal disease. Zimura aims to provide a novel therapeutic approach for AMD and is in advanced clinical development as a complement to traditional anti-VEGF therapies.
|
|
North America
|
In August 2023, Astellas Pharma Inc. announced that IZERVAY (avacincaptad pegol intravitreal solution) will be approved by the U.S. Food and Drug Administration (FDA) to treat geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The rate of GA progression at the 12-month primary endpoint was statistically significantly (p<0.01) lower in two Phase 3 clinical trials with the novel complement C5 inhibitor IZERVAY, making it the only approved treatment for GA.
|
|
5.
|
Genentech, Inc.
|
Genentech, a member of the Roche Group, is a leading biotech company with a strong portfolio in ophthalmology. Genentech markets Lucentis (ranibizumab), a key treatment for wet AMD and other retinal conditions. Lucentis was the first anti-VEGF treatment approved for AMD and remains an important part of Genentech’s portfolio. The company also has a pipeline of other potential retinal disease treatments, including combination therapies, that could further enhance AMD care.
|
|
North America
|
In January 2022, Genentech announced that the U.S. Food and Drug Administration (FDA) had approved Vabysmo (faricimab-svoa) to treat wet AMD and DME. This will help in expanding the product portfolio of the company.
|
Conclusion
The global anti-VEGF market for Age-Related Macular Degeneration (AMD) is expected to witness sustained growth, driven by the rising prevalence of AMD and continuous advancements in treatment options. The introduction of longer-acting therapies and the potential approval of new treatments for geographic atrophy are expanding the market's scope and improving patient outcomes. However, factors such as high treatment costs and competition from off-label alternatives may pose challenges. Despite these hurdles, leading pharmaceutical companies are actively investing in innovation, strategic partnerships, and market expansion to strengthen their position. As the demand for effective AMD treatments grows, the market is likely to evolve with improved accessibility and novel therapeutic developments.
